{"abstract": "The drug, lambrolizumab, significantly shrank melanoma tumors, the company reported on Sunday.", "web_url": "https://www.nytimes.com/2013/06/03/business/merck-has-strong-results-in-a-cancer-drug-trial.html", "snippet": "The drug, lambrolizumab, significantly shrank melanoma tumors, the company reported on Sunday.", "lead_paragraph": "CHICAGO \u2014 An experimental drug from Merck that unleashes the body\u2019s immune system significantly shrank tumors in 38 percent of patients with advanced melanoma, putting the company squarely in the race to bring to market one of what many experts view as the most promising class of drugs in years. ", "print_section": "B", "print_page": "7", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/06/03/business/merck/merck-articleLarge.jpg", "height": 834, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2013/06/03/business/merck/merck-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 834}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/06/03/business/merck/merck-jumbo.jpg", "height": 1024, "width": 737, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/06/03/business/merck/merck-superJumbo.jpg", "height": 1041, "width": 749, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}], "headline": {"main": "Merck Has Solid Results in a Cancer Drug Trial", "kicker": null, "content_kicker": null, "print_headline": "Merck Has Solid Results In a Cancer Drug Trial", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Merck & Company Inc", "rank": 1, "major": "N"}, {"name": "persons", "value": "Pollack, Andrew", "rank": 2, "major": "N"}, {"name": "subject", "value": "Clinical Trials", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "subject", "value": "Melanomas", "rank": 5, "major": "N"}, {"name": "subject", "value": "Cancer", "rank": 6, "major": "N"}, {"name": "organizations", "value": "AMERICAN SOCIETY OF CLINICAL ONCOLOGY", "rank": 7, "major": "N"}], "pub_date": "2013-06-03T00:50:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/8b8635db-c085-5eba-9dfd-1ea97855b5fd", "word_count": 487, "uri": "nyt://article/8b8635db-c085-5eba-9dfd-1ea97855b5fd"}